Cargando…
Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)
BACKGROUND: In locoregionally advanced nasopharyngeal carcinoma (LANPC) patients, variance of tumor response to induction chemotherapy (ICT) was observed. We developed and validated a novel imaging biomarker to predict which patients will benefit most from additional ICT compared with chemoradiother...
Autores principales: | Dong, Di, Zhang, Fan, Zhong, Lian-Zhen, Fang, Meng-Jie, Huang, Cheng-Long, Yao, Ji-Jin, Sun, Ying, Tian, Jie, Ma, Jun, Tang, Ling-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806559/ https://www.ncbi.nlm.nih.gov/pubmed/31640711 http://dx.doi.org/10.1186/s12916-019-1422-6 |
Ejemplares similares
-
Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Li, Wen-Fei, et al.
Publicado: (2016) -
Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019) -
Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?
por: Zheng, Wei, et al.
Publicado: (2015) -
Optimize the number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
por: Jiang, YuTing, et al.
Publicado: (2022) -
Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response
por: Jiang, Yu‐Ting, et al.
Publicado: (2022)